SCHEMBL14711664

SCHEMBL14711664

COC(=O)[C@H]1CCN(c2ccc(B3OC(C)(C)C(C)(C)O3)cc2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
NOTUM Q6P988 6/20 0.41
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PDK2 Q15119 1/20 0.39
USP30 Q70CQ3 1/20 0.39
KDM4E B2RXH2 1/20 0.38
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
ALDH1A1 P00352 1/20 0.37
RAB9A P51151 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
KCNMA1 Q12791 1/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
CA12 O43570 1/20 0.36
CA3 P07451 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14711369 1.00 MAPT (0.50) MAPTNOTUMHSD17B10MEN1KMT2A
SCHEMBL14711308 0.93 MAPT (0.43) MAPTNOTUMMEN1KMT2ASMN1; SMN2
SCHEMBL14710272 0.93 MAPT (0.43) MAPTNOTUMMEN1KMT2ASMN1; SMN2
SCHEMBL14712102 0.93 MAPT (0.43) MAPTNOTUMMEN1KMT2ASMN1; SMN2
SCHEMBL23551462 0.93 MAPT (0.58) MAPTHSD17B10MEN1KMT2ASMN1; SMN2
SCHEMBL15919677 0.87 USP30 (0.45) MAPTNOTUMUSP30
SCHEMBL3374553 0.86 NOTUM (0.46) MAPTNOTUMHSD17B10MEN1KMT2A
SCHEMBL29429497 0.82 MAPT (0.42) MAPTNOTUMHSD17B10PDK2USP30
SCHEMBL22680282 0.82 MAPT (0.42) MAPTNOTUMHSD17B10PDK2USP30
SCHEMBL25447223 0.81 KDM4E (0.44) MAPTMEN1KMT2ASMN1; SMN2USP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 MAPT 4564/4885NOTUM 1014/4885HSD17B10 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.